Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1

International Archives of Allergy and Immunology

Volumn 138, Issue 1, 2005, Pages 59-66

  Gafvelin, Guro ^a   Thunberg, Sarah ^a   Kronqvist, Marianne ^a,b   Grönlund, Hans ^a   Grönneberg, Reidar ^c   Troye Blomberg, Marita ^d   Akdis, Mübeccel ^e   Fiebig, Helmut ^f   Purohit, Ashok ^g   Horak, Friedrich ^h   Reisinger, Jürgen ^h   Niederberger, Verena ^h   Akdis, Cezmi A ^e   Cromwell, Oliver ^f   Pauli, Gabrielle ^g   Valenta, Rudolf ^h   Van Hage, Marianne ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d STOCKHOLM UNIVERSITY   (Sweden)

^e SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

^f ALLERGOPHARMA JOACHIM GANZER KG   (Germany)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Allergen specific immunotherapy; Allergy; Bet v 1; Hypoallergen; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; PLACEBO; POLLEN ANTIGEN; RECOMBINANT BET V 1 ANTIGEN; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BIRCH; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLLEN ALLERGY; PRIORITY JOURNAL; SKIN MANIFESTATION; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; VACCINATION;

ADULT; ALLERGENS; ANTIBODIES; BETULA; CELLS, CULTURED; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PLANT PROTEINS; POLLEN; RECOMBINANT PROTEINS; SKIN TESTS;

EID: 24744449071     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087358     Document Type: Article

References (36)

1. Kapsenberg ML: Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 2003;3:984-993.
2. von Bubnoff D, Geiger E, Bieber T: Antigen-presenting cells in allergy. J Allergy Clin Immunol 2001;108:329-339.
3. Herrick CA, Bottomly K: To respond or not to respond: T cells in allergic asthma. Nat Rev Immunol 2003;3:405-412.
4. Akdis CA, Joss A, Akdis M, Faith A, Blaser K: A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J 2000;14:1666-1668.
5. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, Thunberg S, Deniz G, Valenta R, Fiebig H, Kegel C, Disch R, Schmidt-Weber CB, Blaser K, Akdis CA: Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004;199:1567-1575.
6. Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J, Carr VA, Robinson DS: Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004;363:608-615.
7. Valenta R: The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002;2:446-453.
8. Valenta R, Ball T, Focke M, Linhart B, Mothes N, Niederberger V, Spitzauer S, Swoboda I, Vrtala S, Westritschnig K, Kraft D: Immunotherapy of allergic disease. Adv Immunol 2004;82:105-153.
9. Ball T, Sperr WR, Valent P, Lidholm J, Spitzauer S, Ebner C, Kraft D, Valenta R: Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999;29:2026-2036.
10. Moverare R, Elfman L, Vesterinen E, Metso T, Haahtela T: Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 2002;57:423-430.
11. Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR, Valent P, Ebner C, Kraft D, Valenta R: Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: Candidates for a novel form of specific immunotherapy. J Clin Invest 1997;99:1673-1681.
12. Vrtala S, Hirtenlehner K, Susani M, Akdis M, Kussebi F, Akdis CA, Blaser K, Hufnagl P, Binder BR, Politou A, Pastore A, Vangelista L, Sperr WR, Semper H, Valent P, Ebner C, Kraft D, Valenta R: Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J 2001;15:2045-2047.
13. van Hage-Hamsten M, Kronqvist M, Zetterström O, Johansson E, Niederberger V, Vrtala S, Grönlund H, Grönneberg R, Valenta R: Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen. Bet v 1: Results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 1999;104:969-977.
14. Vrtala S, Akdis CA, Budak F, Akdis M, Blaser K, Kraft D, Valenta R: T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J Immunol 2000;165:6653-6659.
15. Pauli G, Purohit A, Oster JP, de Blay F, Vrtala S, Niederberger V, Kraft D, Valenta R: Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wildtype by skin prick and intradermal testing: Results obtained in a French population. Clin Exp Allergy 2000;30:1076-1084.
16. Nopp A, Hallden G, Lundahl J, Johansson E, Vrtala S, Valenta R, Grönneberg R, van Hage-Hamsten M: Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen Bet v 1 and to recombinant Bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. J Allergy Clin Immunol 2000;106:101-109.
17. van Hage-Hamsten M, Johansson E, Roquet A, Peterson C, Andersson M, Greiff L, Vrtala S, Valenta R, Grönneberg R: Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis. Clin Exp Allergy 2002;32:1448-1453.
18. Mahler V, Vrtala S, Kuss O, Diepgen TL, Suck R, Cromwell O, Fiebig H, Hartl A, Thalhamer J, Schuler G, Kraft D, Valenta R: Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Clin Exp Allergy 2004;34:1-8.
19. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth M-T, Valent P, Reisinger J, Pelzmann M, Hayek B, Kronqvist M, Gafvelin G, Grönlund H, Purohit A, Suck R, Fiebig H, Cromwell O, Pauli G, van Hage-Hamsten M, Valenta R: Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004;101:14677-14682.
20. Gabrielsson S, Söderlund A, Paulie S, van der Pouw Kraan TC, Troye-Blomberg M, Rak S: Specific immunotherapy prevents increased levels of allergen-specific IL-4- and IL-13-producing cells during pollen season. Allergy 2001;56:293-300.
21. elGhazali GE, Paulie S, Andersson G, Hansson Y, Holmquist G, Sun JB, Olsson T, Ekre HP, Troye-Blomberg M: Number of interleukin-4-and interferon-gamma-secreting human T cells reactive with tetanus toxoid and the mycobacterial antigen PPD or phytohemagglutinin: Distinct response profiles depending on the type of antigen used for activation. Eur J Immunol 1993;23:2740-2745.
22. Vrtala S, Susani M, Sperr WR, Valent P, Laffer S, Dolecek C, Kraft D, Valenta R: Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p2, Phl p 5). J Allergy Clin Immunol 1996;97:781-787.
23. Aghayan-Ugurluoglu R, Ball T, Vrtala S, Schweiger C, Kraft D, Valenta R: Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: A study performed with purified recombinant pollen allergens. J Allergy Clin Immunol 2000;105:803-813.
24. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT: Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178:2123-2130.
25. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR: Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187-4194.
26. Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S, Klotz F, Ebner H, Kraft D, Scheiner O: Immunological changes during specific immunotherapy of grass pollen allergy: Reduced lymphoprohferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997;27:1007-1015.
27. Yang X, Gieni RS, Mosmann TR, HayGlass KT: Chemically modified antigen preferentially elicits induction of Th1-like cytokine synthesis patterns in vivo. J Exp Med 1993;178:349-353.
28. Linhart B, Jahn-Schmid B, Verdino P, Keller W, Ebner C, Kraft D, Valenta R: Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J 2002;16:1301-1303.
29. Francis JN, Till SJ, Durham SR: Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003;111:1255-1261.
30. Noun-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, Staple SQ, Aalberse RC, Till SJ, Durham SR: Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004;172:3252-3259.
31. Muller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, Blaser K: Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998;101:747-754.
32. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA: IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:1205-1214.
33. van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J, Ipsen H: Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999;163:2944-2952.
34. Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y, Semper H, Valent P, Niederberger V, Kraft D, Valenta R: Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: Reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003;33:1198-1208.
35. Ravetch JV, Bolland S: IgG Fc receptors. Annu Rev Immunol 2001;19:275-290.
36. Wachholz PA, Soni NK, Till SJ, Durham SR: Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003;112:915-922.